Abstract
The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the [UNICAMP], Brazil. EGFR exons 18–21 were analyzed in tumor-derived DNA. Fifty patients were included in the study (25 with adenocarcinoma). EGFR mutations were identified in 6/50 (12 %) NSCLCs and in 6/25 (24 %) adenocarcinomas; representing the frequency of EGFR mutations in a mostly self-reported White (82.0 %) southeastern Brazilian population of NSCLCs. Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 [95 % CI 1.03–90.41], p = 0.047). We report the frequency of EGFR activating mutations in a typical southeastern Brazilian population with NSCLC, which are similar to that of other countries with Western European ethnicity. EGFR mutations seem to be predictive of a response to platinum-paclitaxel, and additional studies are needed to confirm or refute this relationship.
Similar content being viewed by others
References
Ramalingam SS, Owonikoko TK, Khuri FR (2011) Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin 61(2):91–112. doi:10.3322/caaac.20102
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166
Ettinger DS, Akerley W, Borghaei H et al (2012) Non-small cell lung cancer. J Natl Compr Canc Netw 10(10):1236–1271
Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98
Shepherd FA, Rosell R (2007) Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer. J Thorac Oncol 2(Suppl 2):S68–S76
Danzinger S, Filipitz M (2007) Biomarkers—the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC). Wien Med Wochenschr 157(21-22):554–561. doi:10.1007/s10354-007-0483-x
Ferraldeschi R, Baka S, Jyoti B et al (2007) Modern management of small-cell lung cancer. Drugs 67(15):2135–2152
Lee W, Lockhart AC, Kim RB et al (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111. doi:10.1634/theoncologist.10-2-104
Rosell R, Cobo M, Isla D et al (2005) Application of genomics in NSCLC. Lung Cancer S33–40
Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. doi:10.1056/NEJMoa061884
Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized, phase 3 study. Lancet Oncol 12:735–742. doi:10.1016/s1470-2045(11)70184-x
De Luca A, Carotenuto A, Rachiglio A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214:559–567
Jackman DM, Yeap BY, Sequist LV et al (2006) Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 12(13):3908–3914. doi:10.1158/1078-0432.CCR-06-0462
Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380. doi:10.1056/NEJMra0802714
Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73. doi:10.1371/journal.pmed.0020073
Bacchi CE, Ciol H, Queiroga EM et al (2012) Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients. Clinics (São Paulo, Brazil) 67(5):419–424. doi:10.6061/clinics/2012(05)03
Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500. doi:10.1126/science
Johnson BE, Janne PA (2005) Epidermal growth factor receptor mutations in patients with non–small cell lung cancer. Cancer Res 65:7525–7529. doi:10.1158/00085472.CAN-051257
Lin CC, Hsu HH, Sun CT et al (2010) Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors. Thorac Oncol 9:1424–1429. doi:10.1097/JTO.ob013e318e9db73
Kim HT, Lee JE, Shin ES et al (2008) Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. J Clin Oncol 26(36):5972–5979. doi:10.1200/JCO.2008.16.6496
Zambon, L (1994) Carcinoma Brônquico: Análise de uma série de casos atendidos no ambulatório de oncopneumologia das disciplinas de Pneumologia e Cirúrgia Torácica da Faculdade de Ciências Médicas da UNICAMP. Dissertation, State University of Campinas (UNICAMP), Brasil.
Dogan S, Shen R, Ang DC et al (2012) Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18(22):6169–6177. doi:10.1158/1078-0432CCR-11-3265
Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 36(10):947–957. doi:10.1056/NEJMoa0810699
Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246. doi:10.1016/s1470-2045(11)70393-x
Acknowledgments
The authors thank the staff of thoracic surgery at [UNICAMP] for the collection of endobronchial biopsies and Lúcia Helena Siqueira for helping in cloning the technique. This study have been supported by governmental resources from FAPESP (Fundação de Apoio à Pesquisa no Estado de São Paulo), no 09/52574-5.
Conflict of interest
DBC has received consulting fees from Roche and AstraZeneca. The others authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Honma, H.N., Perroud, M.W., Leme, M.S.T. et al. EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients. Targ Oncol 9, 389–394 (2014). https://doi.org/10.1007/s11523-014-0314-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-014-0314-0